Biogen Idec

www.biogenidec.com

Biogen Idec Photos

Exterior RTP
Bird's Eye View
Interior RTP

+ Add Photo

Biogen Idec Reviews

244 Reviews
4.0
244 Reviews
Rating Trends

Recommend to a friend
Approve of CEO
Biogen Idec CEO and Director George A. Scangos
George A. Scangos
142 Ratings

Biogen Idec Interviews

Updated 16 Jan 2015
Updated 16 Jan 2015

Interview Experience

Interview Experience

59%
26%
13%

Getting an Interview

Getting an Interview

35%
28%
13%

Interview Difficulty

3.0
Average

Interview Difficulty

Hard

Average

Easy
  1.  

    Data Manager Interview

    Anonymous Interview Candidate
    Anonymous Interview Candidate
    Application Details

    I applied in-person. The process took 7 weeksinterviewed at Biogen Idec.

    Interview Details

    Met the hiring manager at a job fair. Was contacted by HR to come in for three in-person interviews with the hiring manager and members of the team. The entire process took a very, very long time (almost two months). I received several other offers during that time and eventually had to call HR to tell them that even though I wanted to work there, I needed to let the other companies know I had accepted another offer. I received the written offer via overnight mail two days later.

    Interview Questions
    • Most unexpected was "which famous person, dead or alive, would you like to have dinner with?   View Answer
    Negotiation Details
    I was able to negotiate my vacation and tuition for my current semester of graduate school
    Accepted Offer
    Neutral Experience
    Easy Interview

Biogen Idec Awards and Accolades

Something missing? Add an award
Top Employer, Science Magazine, 2012
Top Employer, Science Magazine, 2011
Show More

Additional Info

Unlock Profile
Website www.biogenidec.com
Headquarters Cambridge, MA
Size 5000+ Employees
Founded 1978
Type Company - Public (BIIB)
Industry Biotech & Pharmaceuticals
Revenue ₹100 to ₹500 billion (INR) per year
Competitors Unknown

With its pipeline full of biotech drugs, Biogen Idec aims to meet the unmet needs of patients around the world. The biotech giant is focused on developing treatments in the areas of immunology and neurology. Its product roster includes best-selling Avonex, a popular drug for the treatment of relapsing multiple sclerosis (MS); Tysabri, a drug treatment for MS and Crohn's disease (developed with Elan); Rituxan, a monoclonal antibody developed jointly with Genentech that treats non-Hodgkin's lymphoma and rheumatoid arthritis; and Fumaderm, a psoriasis drug marketed in... More

Work at Biogen Idec? Share Your Experiences

Biogen Idec

 
Click to Rate
or